# Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

> **NCT05218889** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Pancreatic Cancer
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreas Cancer
- Pancreatic Neoplasms

## Interventions

- **DRUG:** surufatinib + camrelizumab + nab-paclitaxel + S-1
- **DRUG:** nab-paclitaxel + gemcitabine

## Key facts

- **NCT ID:** NCT05218889
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-04
- **Primary completion:** 2024-12-16
- **Final completion:** 2025-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218889, "Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05218889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*